The NEDD8-activating enzyme E1 UBA3 orchestrates the immunosuppressive microenvironment in lung adenocarcinoma via the NF-кB pathway.


Journal

Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 28 06 2023
accepted: 14 08 2023
medline: 4 9 2023
pubmed: 1 9 2023
entrez: 1 9 2023
Statut: epublish

Résumé

Immunosuppressive cells play important roles in generating an immunosuppressive tumor microenvironment and facilitating tumor immune escape. However, the molecular mechanisms underlying their immunosuppressive effects remain unclear. UBA3, the sole catalytic subunit of the neural precursor cell expressed developmentally down-regulated protein 8 (NEDD8)-activating enzyme E1, is highly expressed in various human malignancies, along with an activated neddylation pathway. In this study, we investigated the relationships between the UBA3-dependent neddylation pathway and the infiltration of several immunosuppressive cell populations in lung adenocarcinoma (LUAD). We explored the regulatory mechanisms of UBA3 in LUAD cells by using mRNA sequencing and functional enrichment analyses. Correlations between neddylation and immune infiltrates were assessed by Western blotting, real-time PCR, and analyses of public databases. We found elevated levels of UBA3 expression in LUAD tissues compared to adjacent normal tissues. Blocking UBA3 and the neddylation pathway promoted the accumulation of the phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (p-IκBα), inhibiting the gene expression of tumor cell-derived cytokines such as C-C motif chemokine ligand (CCL) 2, C-X-C motif ligand (CXCL)1, CXCL2, colony-stimulating factor (CSF) 1, CSF2 interleukin (IL)-6, and IL-1B. Moreover, the overexpression of UBA3 in LUAD cells was associated with the secretion of these cytokines, and the recruitment and infiltration of immunosuppressive cells including tumor-associated macrophages (TAMs), plasmacytoid dendritic cells (pDCs), Th2 cells and T-regulatory cells (Tregs). This could facilitate the tumor immune escape and malignant progression of LUAD. Our findings provide new insights into the role of UBA3 in establishing an immunosuppressive tumor microenvironment by modulating nuclear factor kappa B (NF-кB) signaling and the neddylation pathway.

Identifiants

pubmed: 37656220
doi: 10.1007/s12032-023-02162-y
pii: 10.1007/s12032-023-02162-y
pmc: PMC10474176
doi:

Substances chimiques

Cytokines 0
Ligands 0
NEDD8 Protein 0
NEDD8 protein, human 0
NF-kappa B 0
NAE protein, human EC 6.3.2.-
Ubiquitin-Activating Enzymes EC 6.2.1.45

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

286

Informations de copyright

© 2023. The Author(s).

Références

Oncogene. 2019 Jul;38(29):5792-5804
pubmed: 31243299
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Cancer Sci. 2020 Nov;111(11):4242-4256
pubmed: 32926492
Mol Cancer. 2023 Feb 21;22(1):40
pubmed: 36810079
Int J Pharm. 2021 Apr 1;598:120350
pubmed: 33545279
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Neuro Oncol. 2022 Nov 2;24(11):1869-1870
pubmed: 35749751
Virchows Arch. 2005 May;446(5):475-82
pubmed: 15856292
J Hematol Oncol. 2019 Nov 27;12(1):125
pubmed: 31775797
Sci Rep. 2018 Jul 4;8(1):10108
pubmed: 29973603
Nat Commun. 2021 Jul 7;12(1):4193
pubmed: 34234122
Int J Mol Sci. 2022 Mar 23;23(7):
pubmed: 35408841
Semin Cancer Biol. 2022 Nov;86(Pt 2):146-159
pubmed: 35963564
Cancer Lett. 2012 Sep 28;322(2):119-26
pubmed: 22433713
Mol Cell. 2019 Jan 3;73(1):22-35.e6
pubmed: 30527665
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Oncol Lett. 2018 Jan;15(1):515-521
pubmed: 29387232
J Clin Invest. 2007 Sep;117(9):2570-82
pubmed: 17710230
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Trends Cancer. 2022 Nov;8(11):944-961
pubmed: 35853825
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Mol Cancer. 2019 Apr 3;18(1):77
pubmed: 30943988
J Natl Cancer Inst. 2014 May 22;106(6):dju083
pubmed: 24853380
Front Immunol. 2022 Jan 06;12:802795
pubmed: 35069587
Cancer Immunol Immunother. 2006 May;55(5):598-611
pubmed: 16133109
Int J Mol Sci. 2021 Dec 10;22(24):
pubmed: 34948104
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Cell Death Dis. 2018 Jan 25;9(2):117
pubmed: 29371589
Theranostics. 2021 Feb 19;11(9):4122-4136
pubmed: 33754052
Virchows Arch. 2018 Apr;472(4):589-598
pubmed: 29520483
Biochem Soc Trans. 2008 Oct;36(Pt 5):802-6
pubmed: 18793140
Int Immunopharmacol. 2022 Dec;113(Pt A):109329
pubmed: 36252470
Ann N Y Acad Sci. 2021 Sep;1499(1):18-41
pubmed: 32445205
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
Immunity. 2019 Jan 15;50(1):37-50
pubmed: 30650380
Front Immunol. 2023 Jun 26;14:1154881
pubmed: 37435086
Front Cell Dev Biol. 2022 Sep 13;10:979262
pubmed: 36176276
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Gut. 2018 Sep;67(9):1692-1703
pubmed: 28866620
Life Sci. 2020 Nov 1;260:118476
pubmed: 32971102
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830

Auteurs

Xiongzhi Lin (X)

Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, China.
Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.

Shuhan Yang (S)

Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, China.
Medical School, Taizhou University, Taizhou, Zhejiang, China.

Caichuan Zhou (C)

Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, China.
Medical School, Taizhou University, Taizhou, Zhejiang, China.

Chengcheng Ao (C)

Taizhou Central Hospital (Taizhou University Hospital), Taizhou University, Taizhou, Zhejiang, China.
Medical School, Taizhou University, Taizhou, Zhejiang, China.

Dongsheng Sun (D)

Medical School, Taizhou University, Taizhou, Zhejiang, China. sunds@tzc.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH